Research programme: small-molecule cancer therapeutics - Compugen
Alternative Names: CGEN-50001Latest Information Update: 03 Nov 2010
At a glance
- Originator Compugen
- Class Small molecules
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Nov 2010 No development reported for CGEN 50001 - Preclinical for Cancer in Israel (IV)
- 16 Jul 2008 Preclinical trials in Cancer in Israel (IV)